- Home
- XXII vs LIPO Comparison
XXII vs LIPO Comparison
Compare XXII & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- LIPO
- Stock Information
- Founded
- XXII 1998
- LIPO 2005
- Country
- XXII United States
- LIPO United States
- Employees
- XXII N/A
- LIPO N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- LIPO Health Care
- Exchange
- XXII Nasdaq
- LIPO Nasdaq
- Market Cap
- XXII 2.8M
- LIPO 3.1M
- IPO Year
- XXII N/A
- LIPO 2022
- Fundamental
- Price
- XXII $3.15
- LIPO $3.14
- Analyst Decision
- XXII
- LIPO Strong Buy
- Analyst Count
- XXII 0
- LIPO 1
- Target Price
- XXII N/A
- LIPO $16.00
- AVG Volume (30 Days)
- XXII 166.3K
- LIPO 6.6M
- Earning Date
- XXII 03-27-2025
- LIPO 02-28-2025
- Dividend Yield
- XXII N/A
- LIPO N/A
- EPS Growth
- XXII N/A
- LIPO N/A
- EPS
- XXII N/A
- LIPO N/A
- Revenue
- XXII $17,304,000.00
- LIPO $483,533.00
- Revenue This Year
- XXII $56.94
- LIPO N/A
- Revenue Next Year
- XXII $2.98
- LIPO N/A
- P/E Ratio
- XXII N/A
- LIPO N/A
- Revenue Growth
- XXII N/A
- LIPO 0.78
- 52 Week Low
- XXII $3.01
- LIPO $2.21
- 52 Week High
- XXII $581.85
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- XXII 35.94
- LIPO 48.05
- Support Level
- XXII $3.01
- LIPO $3.35
- Resistance Level
- XXII $3.47
- LIPO $4.69
- Average True Range (ATR)
- XXII 0.33
- LIPO 0.62
- MACD
- XXII 0.11
- LIPO -0.02
- Stochastic Oscillator
- XXII 11.29
- LIPO 13.31
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.